Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis.

ABSTRACT:

Introduction

The Janus kinase (JAK)1/2 inhibitor ruxolitinib provides rapid, sustained and often dramatic benefits to patients with myelofibrosis, inducing spleen shrinkage and ameliorating symptoms, and improves survival. However, the drug has little effect on the underlying bone marrow fibrosis or on mutant allele burden, and clinical resistance eventually develops. Furthermore, ruxolitinib-induced cytopenias can be challenging in everyday practice.

Areas covered

The developmental therapeutics landscape in MF is discussed. This includes potential partners for ruxolitinib being developed with an aim to improve cytopenias, or to enhance its disease-modifying effects. The development of other JAK inhibitors with efficacy post-ruxolitinib or other unique attributes is being pu

SUBMITTER: Bose P 

PROVIDER: S-EPMC7577425 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature